{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319965545600.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1128/aac.41.7.1444"}},{"identifier":{"@type":"URI","@value":"https://journals.asm.org/doi/pdf/10.1128/AAC.41.7.1444"}}],"dc:title":[{"@value":"Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>BMS-200475 is a novel carbocyclic 2'-deoxyguanosine analog found to possess potent and selective anti-hepatitis B virus (anti-HBV) activity. BMS-200475 is distinguished from guanosine by replacement of the natural furanose oxygen on the sugar moiety with an exo carbon-carbon double bond. In the HepG2 stably transfected cell line 2.2.15, BMS-200475 had a 50% effective concentration (EC50) of 3.75 nM against HBV, as determined by analysis of secreted HBV DNA. Structurally related compounds with adenine, iodouracil, or thymine base substitutions were significantly less potent or were inactive. Direct comparison of the antiviral activities of BMS-200475 with those of a variety of other nucleoside analogs, including lamivudine (EC50 = 116.26 nM), demonstrated the clearly superior in vitro potency of BMS-200475 in 2.2.15 cells. Intracellular HBV replicative intermediates were uniformly reduced when cells were treated with BMS-200475, but rebounded after treatment was terminated. The concentration of BMS-200475 causing 50% cytotoxicity in 2.2.15 cell cultures was 30 microM, approximately 8,000-fold greater than the concentration required to inhibit HBV replication in the same cell line. Treatment with BMS-200475 resulted in no apparent inhibitory effects on mitochondrial DNA content.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380285709249664907","@type":"Researcher","foaf:name":[{"@value":"S F Innaimo"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319965545600","@type":"Researcher","foaf:name":[{"@value":"M Seifer"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319965545602","@type":"Researcher","foaf:name":[{"@value":"G S Bisacchi"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319965545474","@type":"Researcher","foaf:name":[{"@value":"D N Standring"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319965545472","@type":"Researcher","foaf:name":[{"@value":"R Zahler"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319965545601","@type":"Researcher","foaf:name":[{"@value":"R J Colonno"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00664804"},{"@type":"EISSN","@value":"10986596"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00664804"}],"prism:publicationName":[{"@value":"Antimicrobial Agents and Chemotherapy"}],"dc:publisher":[{"@value":"American Society for Microbiology"}],"prism:publicationDate":"1997-07","prism:volume":"41","prism:number":"7","prism:startingPage":"1444","prism:endingPage":"1448"},"reviewed":"false","dc:rights":["https://journals.asm.org/non-commercial-tdm-license"],"url":[{"@id":"https://journals.asm.org/doi/pdf/10.1128/AAC.41.7.1444"}],"createdAt":"2018-10-09","modifiedAt":"2022-02-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233130624000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Diastereoselective Synthesis of 6″-(<i>Z</i>)- and 6″-(<i>E</i>)-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235964855808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Postexposure Prophylactic Effect of Hepatitis B Virus (HBV)-Active Antiretroviral Therapy against HBV Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705276763136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Synthesis of 4′‐Substituted Purine 2′‐Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707257585408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Characterization of novel entecavir resistance mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709249664896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Design, Synthesis, and Evaluation of Anti-HBV Activity of Hybrid Molecules of Entecavir and Adefovir: Exomethylene Acycloguanine Nucleosides and Their Monophosphate Derivatives"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643825452032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567184226403840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A novel entecavir analogue constructing with a spiro[2.4]heptane core structure in the aglycon moiety: Its synthesis and evaluation for anti-hepatitis B virus activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185744262272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics studies of 4′-cyano-2′-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658081416576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Synthesis, Anti-HBV, and Anti-HIV Activities of 3′-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658414012544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848662555463552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679247500800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological and clinical profile of lamivudine(Zefix)."},{"@language":"ja","@value":"抗ＨＢＶ薬ラミブジン（ゼフィックス錠１００）の薬理作用と臨床効果"},{"@value":"新薬紹介総説 抗HBV薬ラミブジン(ゼフィックス錠100)の薬理作用と臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ コウHBVヤク ラミブジン ゼフィックスジョウ 100 ノ ヤクリ サヨウ ト リンショウ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679248999040","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Ｂ型慢性肝炎治療薬エンテカビル水和物（バラクルード錠０．５ｍｇ）の薬理学的特性と臨床効果"},{"@language":"en","@value":"Pharmacological properties and clinical efficacy of entecavir monohydrate (Baraclude<sup>®</sup> Tablet 0.5 mg), an anti-HBV drug"},{"@value":"新薬紹介総説 B型慢性肝炎治療薬エンテカビル水和物(バラクルード錠0.5mg)の薬理学的特性と臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ Bガタ マンセイ カンエン チリョウヤク エンテカビル スイワブツ バラクルードジョウ 0 5mg ノ ヤクリガクテキ トクセイ ト リンショウ コウカ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1128/aac.41.7.1444"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1128/aac.04459-14_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1002/slct.201800527_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1080/15257770.2015.1037456_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1254/fpj.120.55_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1128/jvi.02401-20_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1080/15257770.2017.1322209_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1111/jphp.12897_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1021/acsmedchemlett.8b00374_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1038/s41598-018-19602-9_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0198636_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1254/fpj.129.287_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1021/acs.joc.6b00105_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2015.03.020_references_DOI_XBo1UAbNaFfMeFqsAaNceKSuDI8"}]}